Principal

ALO Collaborates with The Education University of Hong Kong

Retrieved on: 
Tuesday, March 26, 2024
Well, Learning, Artificial intelligence, Psychology, Secondary school, Parent, Commerce, Love, Methodism, Curriculum, Yuen Yuen Institute, Communication, Speech, Committee, Kornhill, Special needs, Education University, Safety, Kaiping, Curriculum framework, Teaching, Shatin Pui Ying College, Bias, Knowledge, HKTA, AI, Parenting, Student, Indian Olympic Association, Education Bureau, Lip, Principal, Motivation, Growth, Environment, School, Gold, Special Olympics, Workload, Tutoring

HONG KONG, Mar 26, 2024 - (ACN Newswire) - ALO Parent Education App/Digital Platform (ALO) is collaborating with The Education University of Hong Kong (EdUHK) to provide greater support for students with special educational needs (SEN) and their parents.

Key Points: 
  • HONG KONG, Mar 26, 2024 - (ACN Newswire) - ALO Parent Education App/Digital Platform (ALO) is collaborating with The Education University of Hong Kong (EdUHK) to provide greater support for students with special educational needs (SEN) and their parents.
  • The collaboration between ALO, EdUHK, and the Hong Kong Police Force serves as a testament to the importance of interdisciplinary and cross-professional cooperation.
  • In the upcoming enhanced version, ALO 4.0, we will introduce new categories such as 'Special Education,' 'National Education,' and 'Law-abidingness Education.'
  • In the future, ALO will stay true to its original mission of 'Unite Hong Kong to Support Parents ; Build a Prosperous Society Through Positive Parenting,' contributing to the construction of a prosperous society in Hong Kong!"

Electric Sheep Robotics Wins 2024 RBR50 Robotics Innovation Award, Startup of the Year

Retrieved on: 
Tuesday, April 9, 2024
Principal, Electric Sheep, Organization, Venture capital, Electricity, SAN, Knowledge, Artificial intelligence, Robotics, AI, RAM, Partner, ES1, Reinforcement, Medical device

SAN FRANCISCO, April 09, 2024 (GLOBE NEWSWIRE) -- Electric Sheep , who is creating the first large-scale outdoor maintenance company powered by artificial intelligence and robotics, announced that it has been named 2024 RBR50 Robotics Innovation Award as Start up the Year .

Key Points: 
  • SAN FRANCISCO, April 09, 2024 (GLOBE NEWSWIRE) -- Electric Sheep , who is creating the first large-scale outdoor maintenance company powered by artificial intelligence and robotics, announced that it has been named 2024 RBR50 Robotics Innovation Award as Start up the Year .
  • Electric Sheep is acquiring traditional outdoor service providers and progressively transforming operations by deploying proprietary AI software and robots.
  • Electric Sheep robotics are currently deployed in hundreds of customer sites running robots daily and improving the performance of its foundational AI world models.
  • At the Robotics Summit and Expo, Electric Sheep will demo its newest robot, Verdie in the RBR Showcase.

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies 

Retrieved on: 
Monday, April 8, 2024
Principal, Malignancy, Risk, Patient, Food and Drug Administration, City, CRS, NHL, Mutagenesis, Therapy, Hematology, Bone marrow, B-cell lymphoma, APOLLO, Neurotoxicity, DLBCL, Cytokine release syndrome, Lymphoma, Press release

HOUSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported that Geoffrey Shouse, D.O., Ph.D., the Principal Investigator at City of Hope National Medical Center in Duarte, CA, was invited to present his clinical experience from the APOLLO study at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada (April 2-7, 2024). Dr. Shouse provided an overview on the clinical observations obtained at City of Hope on Saturday, April 6, 2024.

Key Points: 
  • Dr. Shouse provided an overview on the clinical observations obtained at City of Hope on Saturday, April 6, 2024.
  • During the presentation, Dr. Shouse showed that this study participant remains in CR nine months following initial treatment with MT-601.
  • This APOLLO participant had diffuse large B cell lymphoma (DLBCL) and failed four prior lines of therapy, including anti-CD19 CAR T cell therapy.
  • Dr. Shouse’s presentation included data from two additional study participants that have been treated at City of Hope.

Cielo Announces Closing of Second Tranche of Private Placement of Convertible Debenture Units

Retrieved on: 
Friday, April 5, 2024
Indian stock exchange, Principal, Private, Exchange, Convertible bond, Forced conversion, Issue date, Placement, CMC, Sale, News, Debt, Carbon, Debenture, Convertible, Acceleration, Finance Secretary (India), Calendar, Tranche, NEWS, Conversion, Security (finance)

CALGARY, Alberta, April 05, 2024 (GLOBE NEWSWIRE) -- Cielo Waste Solutions Corp. (TSXV:CMC; OTCQB:CWSFF) (“Cielo” or the “Company”), a renewable fuel company leveraging market ready licensed technology to produce low carbon fuel from wood by-products, is pleased to announce the closing of the second tranche (“Tranche 2”), for gross proceeds of C $1,480,000, of its previously announced non-brokered private placement offering of unsecured convertible debenture units of the Company (collectively, the "Convertible Debenture Units") at a price of C $1,000 per Convertible Debenture Unit for aggregate gross proceeds of up to C $5,000,000 (the "Private Placement"). The Company intends to continue to offer the Convertible Debenture Units on the same terms and close one or more subsequent tranches during the month of April 2024.

Key Points: 
  • CALGARY, Alberta, April 05, 2024 (GLOBE NEWSWIRE) -- Cielo Waste Solutions Corp. (TSXV:CMC; OTCQB:CWSFF) (“Cielo” or the “Company”), a renewable fuel company leveraging market ready licensed technology to produce low carbon fuel from wood by-products, is pleased to announce the closing of the second tranche (“Tranche 2”), for gross proceeds of C $1,480,000, of its previously announced non-brokered private placement offering of unsecured convertible debenture units of the Company (collectively, the "Convertible Debenture Units") at a price of C $1,000 per Convertible Debenture Unit for aggregate gross proceeds of up to C $5,000,000 (the "Private Placement").
  • The Company intends to continue to offer the Convertible Debenture Units on the same terms and close one or more subsequent tranches during the month of April 2024.
  • Pursuant to the closing of Tranche 2, the Company issued 1,480 Convertible Debenture Units for gross proceeds of C $1,480,000, consisting of 1,480 Convertible Debentures and 3,700,000 Warrants.
  • As the Convertible Debentures will be unsecured debt obligations of the Company, each Convertible Debenture will rank subordinate to all secured debt obligations of the Company.

Investigation into Exscientia Underway: Johnson Fistel, LLP Digs into Alleged Securities Law Violations - What Shareholders Need to Know

Retrieved on: 
Wednesday, April 3, 2024
Principal, SAN, Investment, News, LLP

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of securities laws by Exscientia plc (NASDAQ: EXAI) ("Exscientia" or "the Company").

Key Points: 
  • SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of securities laws by Exscientia plc (NASDAQ: EXAI) ("Exscientia" or "the Company").
  • If you have purchased Exscientia securities and have experienced losses, we encourage you to join our investigation to potentially make claims and recover under federal securities laws.
  • What if I purchased Exscientia securities?
  • Further details emerged as a special committee of the board enlisted outside counsel to investigate the alleged conduct of the executive.

TearSolutions, Inc. Appoints Louis M Alpern, MD, MPH, FACS, FICS to its Board of Directors

Retrieved on: 
Wednesday, April 3, 2024
Principal, Harvard Medical School, Alpern, Public, Public health, FICS, Private practice, Telecanthus, Patient, DED, MPH, Therapy, FACS, Frustration, Ophthalmology, Pharmaceutical industry

“Dr.

Key Points: 
  • “Dr.
  • Alpern brings extensive real-world clinical experience treating patients with ocular surface disease, having prescribed or trialed virtually every dry eye treatment available,” said Anil Asrani, President and CEO of TearSolutions.
  • “Dr.
  • He received his Doctor of Medicine from Harvard Medical School and his Master of Public Health from the Harvard School of Public Health.

ANEEL™ Fuel Irradiation Begins in the Advanced Test Reactor at Idaho National Lab

Retrieved on: 
Monday, April 1, 2024
Principal, PIE, Idaho National Laboratory, Face, PHWR, INL, Climate, Strategic partnership, ATR, Private sector, ANEEL, Thorium, Nuclear energy, HALEU, DOE, Core, Advanced Test Reactor, Uranium mining

CHICAGO, April 01, 2024 (GLOBE NEWSWIRE) -- Clean Core Thorium Energy (Clean Core) announced today that the accelerated irradiation testing and qualification of their patented ANEEL™ Fuel is set to begin in the Advanced Test Reactor (ATR) at the Idaho National Laboratory (INL). The fuel, made of thorium and high-assay low-enriched uranium (HALEU), was developed by Clean Core for use in pressurized heavy water reactors (PHWRs) and Canada deuterium uranium (CANDU) reactors. Its insertion into one of the US government’s premier material testing facilities represents a key milestone in the company’s multi-year, multimillion-dollar joint effort with the US Department of Energy (DOE) to design, fabricate, and assemble the irradiation experiment.

Key Points: 
  • CHICAGO, April 01, 2024 (GLOBE NEWSWIRE) -- Clean Core Thorium Energy (Clean Core) announced today that the accelerated irradiation testing and qualification of their patented ANEEL™ Fuel is set to begin in the Advanced Test Reactor (ATR) at the Idaho National Laboratory (INL).
  • In 2022, Clean Core signed a Strategic Partnership Project Agreement with INL to design and execute an irradiation experiment in ATR to demonstrate and assess the performance of Clean Core’s innovative Advanced Nuclear Energy for Enriched Life (ANEEL™) fuel.
  • Upon receipt, INL developed the irradiation test plan, performed pre-irradiation characterization of the fuel pellets, designed and fabricated the experiment hardware and test trains, assembled the test trains, and finally inserted the experiment into the ATR.
  • “Clean Core is focused on the efficient development and deployment of the ANEEL fuel in heavy water reactors, without any modifications to the fuel bundle geometry or the reactor.

TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs

Retrieved on: 
Wednesday, March 27, 2024
Principal, Annual, Fungal infection, TFF, COVID, Intubation, International Society, Part, Patient, Biomarker, IPA, Spirometry, EAP, Mortality, Lung transplantation, Microsoft Access, Potential, Safety, Kidney, Heart, Pharmaceutical industry

FORT WORTH, Texas , March 27, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced updated data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) clinical programs.

Key Points: 
  • “Based on the totality of these clinical data, we believe TFF TAC and TFF VORI have the potential to establish a new and significantly improved form of delivery for these two life-saving medicines.
  • The updated safety and efficacy data are based on the cutoff date of March 8, 2024.
  • The ongoing Phase 2 trial of TFF TAC is an open-label study in lung transplant patients who require reduced tacrolimus blood levels due to kidney toxicity.
  • The Company will host a conference call today at 4:30 pm Eastern Time, to discuss updated data for the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) clinical programs.

TruGolf Announces Global Franchising with Franchise Well to Accelerate Growth

Retrieved on: 
Wednesday, March 27, 2024
Well, Principal, Ageing, Golf, Growth, Development, Video game

This relationship marks a pivotal moment for TruGolf as it harnesses the power of franchising to amplify its global presence and cater to the burgeoning demand for immersive off-course golf experiences.

Key Points: 
  • This relationship marks a pivotal moment for TruGolf as it harnesses the power of franchising to amplify its global presence and cater to the burgeoning demand for immersive off-course golf experiences.
  • This collaboration comes at a time when the franchising market is experiencing a significant shift towards experience-based and recreational concepts.
  • Franchising serves as a capital-efficient model to drive our growth and fuel global expansion.
  • This relationship with Franchise Well accelerates our growth and allows us to deploy our innovative technology to even more enthusiasts around the world.”
    The collaboration with Franchise Well will propel TruGolf’s growth strategy forward through the regional developer franchise model, targeting seasoned franchise owners to spearhead expansion.

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 27, 2024
Principal, PDSB, NCI, Head, Survival, Associate, Incidence, Patient, National Cancer Institute, Cancer, Doctor of Philosophy, Biotechnology, Overalls, Oncology, Neck, ICI, Clinical trial, Immune system, IL-12, ICIS, FDA, Physician, PDS, Food, Pharmaceutical industry

This decision enables PDS Biotech to focus its resources on the drug regimen it believes has the highest potential to benefit patients with HNSCC and to drive shareholder value.

Key Points: 
  • This decision enables PDS Biotech to focus its resources on the drug regimen it believes has the highest potential to benefit patients with HNSCC and to drive shareholder value.
  • “We have had several discussions with key opinion leaders in HNSCC regarding the use of the triple combination in HNSCC.
  • The NCI clinical trial data show significant promise in the use of PDS01ADC in combination with Versamune® HPV,” said Katharine A.
  • The event will be archived on the Investor Relations section of PDS Biotech’s website for six months.